Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 91-96

  Garimella, Pranav S ^a   Ix, Joachim H ^b   Katz, Ronit ^c   Chonchol, Michel B ^d   Kestenbaum, Bryan R ^c   de Boer, Ian H ^c   Siscovick, David S ^c   Shastri, Shani ^e   Hiramoto, Jade S ^f   Shlipak, Michael G ^f   Sarnak, Mark J ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ankle brachial index; Cardiovascular disease; Chronic kidney disease; Fibroblast growth factor; Peripheral artery disease

Indexed keywords

ALBUMIN; CREATININE; FIBROBLAST GROWTH FACTOR 23;

AGED; ALBUMIN URINE LEVEL; ANKLE BRACHIAL INDEX; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; URINE LEVEL; VERY ELDERLY;

ANKLE-BRACHIAL INDEX; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; FIBROBLAST GROWTH FACTOR; PERIPHERAL ARTERY DISEASE;

AGED; ANKLE BRACHIAL INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FIBROBLAST GROWTH FACTORS; HUMANS; INCIDENCE; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS;

EID: 84893849556     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.015     Document Type: Article

References (47)

1. O'Hare A.M., Glidden D.V., Fox C.S., Hsu C.Y. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004, 109(3):320-323.
2. Selvin E., Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey. Circulation 2004, 110:738-743.
3. Lijmer J.G., Hunink M.G., van den Dungen J.J., Loonstra J., Smit A.J. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 1996, 22(4):391-398.
4. Ix J.H., Katz R., De Boer I.H., et al. Association of chronic kidney disease with the spectrum of ankle brachial index the CHS (Cardiovascular Health Study). JAm Coll Cardiol Sep 22 2009, 54(13):1176-1184.
5. Leskinen Y., Salenius J.P., Lehtimaki T., Huhtala H., Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis Sep 2002, 40(3):472-479.
6. Adragao T., Pires A., Branco P., et al. Ankle-brachial index, vascular calcifications and mortality in dialysis patients. Nephrol Dial Transplant 2012 Jan, 27(1):318-325.
7. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant Sep 2003, 18(9):1731-1740.
8. O'Hare A.M., Katz R., Shlipak M.G., Cushman M., Newman A.B. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation Jan 24 2006, 113(3):388-393.
9. Gutierrez O., Isakova T., Rhee E., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. JAm Soc Nephrol Jul 2005, 16(7):2205-2215.
10. Gutierrez O.M., Mannstadt M., Isakova T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. NEngl J Med Aug 7 2008, 359(6):584-592.
11. Isakova T., Xie H., Yang W., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAm Med Assoc Jun 15 2011, 305(23):2432-2439.
12. Parker B.D., Schurgers L.J., Brandenburg V.M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med May 18 2010, 152(10):640-648.
13. Ix J.H., Shlipak M.G., Wassel C.L., Whooley M.A. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant Mar 2010, 25(3):993-997.
14. Jean G., Terrat J.C., Vanel T., et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant Sep 2009, 24(9):2792-2796.
15. Moldovan D., Moldovan I., Rusu C., Kacso I., Patiu I.M., Gherman-Caprioara M. FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients. Int Urol Nephrol Apr 3 2013.
16. Desjardins L., Liabeuf S., Renard C., et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int Jul 2012, 23(7):2017-2025.
17. Inaba M., Okuno S., Imanishi Y., et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int Oct 2006, 17(10):1506-1513.
18. Schoppet M., Hofbauer L.C., Brinskelle-Schmal N., et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO Study. JClin Endocrinol Metab Apr 2012, 97(4):E575-E583.
19. Khan A.M., Chirinos J.A., Litt H., Yang W., Rosas S.E. FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol Dec 2012, 7(12):2017-2022.
20. Srivaths P.R., Goldstein S.L., Silverstein D.M., Krishnamurthy R., Brewer E.D. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol Jun 2011, 26(6):945-951.
21. Scialla J.J., Lau W.L., Reilly M.P., et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int Jun 2013, 83(6):1159-1168.
22. Kendrick J., Cheung A.K., Kaufman J.S., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. JAm Soc Nephrol Oct 2011, 22(10):1913-1922.
23. Fried L.P., Borhani N.O., Enright P., et al. The cardiovascular health study: design and rationale. Ann Epidemiol Feb 1991, 1(3):263-276.
24. Jonsson K.B., Zahradnik R., Larsson T., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. NEngl J Med Apr 24 2003, 348(17):1656-1663.
25. Newman A.B., Shemanski L., Manolio T.A., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol Mar 1999, 19(3):538-545.
26. Tell G.S., Rutan G.H., Kronmal R.A., et al. Correlates of blood pressure in community-dwelling older adults. The Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. Hypertension Jan 1994, 23(1):59-67.
27. Psaty B.M., Kuller L.H., Bild D., et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol Jul 1995, 5(4):270-277.
28. Ives D.G., Fitzpatrick A.L., Bild D.E., et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol Jul 1995, 5(4):278-285.
29. Price T.R., Psaty B., O'Leary D., Burke G., Gardin J. Assessment of cerebrovascular disease in the Cardiovascular Health Study. Ann Epidemiol Sep 1993, 3(5):504-507.
30. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem Jun 1972, 18(6):499-502.
31. Erlandsen E.J., Randers E., Kristensen J.H. Evaluation of the Dade Behring N latex cystatin C assay on the Dade Behring nephelometer II system. Scand J Clin Lab Invest Feb 1999, 59(1):1-8.
32. Stevens L.A., Coresh J., Schmid C.H., et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis Mar 2008, 51(3):395-406.
33. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012, 2:337-414.
34. Ix J.H., Katz R., Kestenbaum B.R., et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). JAm Coll Cardiol Jul 17 2012, 60(3):200-207.
35. Mirza M.A., Larsson A., Lind L., Larsson T.E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis Aug 2009, 205(2):385-390.
36. Mirza M.A., Hansen T., Johansson L., et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant Oct 2009, 24(10):3125-3131.
37. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. JClin Invest Nov 2011, 121(11):4393-4408.
38. Jovanovich A., Ix J.H., Gottdiener J., et al. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis Nov 2013, 231(1):114-119.
39. Gutierrez O.M., Januzzi J.L., Isakova T., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation May 19 2009, 119(19):2545-2552.
40. Fliser D., Kollerits B., Neyer U., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. JAm Soc Nephrol Sep 2007, 18(9):2600-2608.
41. Titan S.M., Zatz R., Graciolli F.G., et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011 Feb, 6(2):241-247.
42. Hypertension: evidence update March 2013: a summary of selected new evidence relevant to NICE clinical guideline 127 'clinical management of primary hypertension in adults' 2011, National Clinical Guideline Centre, UK.
43. Semba R.D., Fink J.C., Sun K., et al. Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol Jan 2012, 7(1):85-91.
44. Lundberg S., Qureshi A.R., Olivecrona S., Gunnarsson I., Jacobson S.H., Larsson T.E. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol May 2012, 7(5):727-734.
45. Vervloet M.G., van Zuilen A.D., Heijboer A.C., et al. Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort. BMC Nephrol 2012, 13:20.
46. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int Dec 2003, 64(6):2272-2279.
47. Marsell R., Grundberg E., Krajisnik T., et al. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Eur J Endocrinol Jan 2008, 158(1):125-129.